The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Provident Financial Up On Better Outlook

Wed, 26th Aug 2020 10:40

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 100 - WINNERS

----------

Aveva Group, up 3.5%. The industrial software company was extending gains after announcing on it had agreed to buy US rival OSIsoft for USD5 billion. The stock closed up 7.3% on Tuesday.

----------

FTSE 100 - LOSERS

----------

Polymetal International, down 0.5%. Shares were lower despite the Russian gold miner doubling its interim dividend as a much higher gold price boosted performance. Revenue jumped 17% to USD1.14 billion from USD941 million, and net earnings more than doubled to USD381 million from USD153 million. Polymetal declared a USD0.40 per share interim dividend, twice its USD0.20 per share dividend the year before. The stock remains 62% higher so far in 2020.

----------

FTSE 250 - WINNERS

----------

Provident Financial, up 17%. The subprime lender's shares were sharply higher despite swinging to an interim loss and scrapping its dividend. For the six months ended June 30, Provident swung to a pretax loss of GBP28 million from a profit of GBP43.1 million a year prior. This was as revenue fell 11% to GBP445.6 million from GBP501.5 million. No interim dividend was declared, compared to 9.0p paid for the first half of 2020, as Provident said it needs to preserve capital and provide financial stability. However, Provident said it built strong capital and liquidity positions during the period, with regulatory capital of GBP705 million at the end of June. This equates to a CET1 ratio of 35.4% and a surplus of GBP215 million above the minimum regulatory requirement. Looking ahead, Provident noted since the end of June, there were some encouraging signs of increased activity levels in its markets, with improving customer demand and spending trends evident.

----------

Inchcape, up 5.0%. JPMorgan raised the car dealer to Overweight from Neutral.

----------

Go-Ahead Group, up 4.1%. The transport operator said the Land Transport Authority of Singapore has granted a two-year extension to the contract allowing its Singaporean arm to continue bus operations. Go-Ahead said the extension allows it to continue operating around 450 buses in the Loyang region, which is in the east of the island near Singapore Changi Airport. The extension will begin in September 2021 and run until September 2023. This follows the initial five-year contract which saw the company's entry into the Singapore bus market in September 2016, Go-Ahead said.

----------

WH Smith, up 3.0%. Goldman Sachs started coverage on the books and stationery retailer with a Buy rating.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

4D Pharma, up 32%. The pharmaceutical company said results of Part A of its Phase I/II trial of MRx0518 in combination with immune checkpoint inhibitor Keytruda were "extremely encouraging". MRx0518 is single strain live biotherapeutic product in development for the treatment of cancer. 4D said in 12 patients with metastatic renal cell carcinoma and metastatic non-small cell lung cancer, the combination of MRx0518 with Keytruda achieved a disease control rate of 42%, with five of the 12 patients experiencing a clinically meaningful benefit from the combination. Three patients saw their tumours shrink by around 30%.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Vela Technologies, down 43%. The suspension of trading in Vela shares was lifted on Wednesday after the tech investor completed a capital restructure. Vela on Monday got approval from share and bond holders for disposal of some assets, plus a share capital reorganisation and the conversion of GBP550,000 of outstanding bonds to shares, as well as a GBP1.0 million share placing. The Bingley-headquartered company's suspension on AIM was lifted with bond conversion shares, placing shares, fee shares, broker shares, and new ordinary shares all admitted to trading. Following admission, Vela has 7.17 billion shares in issue.

----------

Pebble Beach Systems Group, down 17%. The software firm said Covid-19 hit its order intake in the first six months of 2020, with customers a bit more cautious about pursuing large projects. In the period to June 30, Pebble Beach's revenue fell 20% year-on-year to GBP4.5 million from GBP5.6 million. Pretax profit, however, rose 3.4% to GBP739,000 from GBP715,000. Sales and marketing expenses were trimmed by 14% to GBP901,000, research and development expenses by 16% to GBP605,000, and administrative costs by 15% to GBP878,000. Orders received were 26% lower during the half at GBP3.9 million from GBP5.2 million a year earlier.

----------

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
6 Jan 2020 08:42

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

4D Pharma To Trial MRx0518 For Pancreatic Cancer Treatment

Read more
6 Nov 2019 11:00

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

UK WINNERS & LOSERS SUMMARY: Vodafone Up, BT Down On Virgin Media Deal

Read more
6 Nov 2019 09:36

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

4D Pharma Says MRx0518 and KEYTRUDA Combination Is Well Tolerated

Read more
5 Nov 2019 15:13

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

PRESS: Consortium Circles Healthcare Assets Of Fund Manager Woodford

Read more
8 Oct 2019 10:35

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

WINNERS & LOSERS SUMMARY: Recruitment Firms Drop Amid Weak UK Market

Read more
8 Oct 2019 09:14

4d Pharma And Merck To Collaborate On Gut Disease Treatments

4d Pharma And Merck To Collaborate On Gut Disease Treatments

Read more
8 Oct 2019 08:30

4D Pharma inks research collaboration agreement with Merck & Co

(Sharecast News) - 4D Pharma has entered into a research collaboration agreement with Merck & Co to discover and develop live biotherapeutics for vaccines.

Read more
30 Sep 2019 09:33

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

4D Pharma Loss Deepens On Currency Headwinds As Pipeline Progresses

Read more
27 Aug 2019 16:45

4D Pharma Appoints Sangamo Therapeutics Boss Macrae To Board

(Alliance News) - 4D Pharma PLC said Tuesday that it has appointed Sandy Macrae as an independent non-executive director with immediate effect.Macrae currently serves as president & of

Read more
25 Jul 2019 11:26

4d Pharma Picks New Candidate; Encouraging Data On Lead Biotherapeutic

(Alliance News) - 4d Pharma PLC on Thursday announced positive preclinical data on lead biotherapeutic candidate MRx0518 and the identification of a new candidate as well.The new candidate,

Read more
8 Jul 2019 09:29

4d Pharma Begins Live Biotherapeutics Asthma Programme

(Alliance News) - 4d Pharma PLC said Monday it has started a phase I/II study for its lead live biotherapeutic candidate for asthma.The double-blind, placebo-controlled study will enrol 90

Read more
13 Jun 2019 16:07

UK Shareholder Meetings Calendar - Next 7 Days

Friday 14 JuneMP Evans GroupSerabi GoldMonday 17 JuneChallenger 18

Read more
30 May 2019 14:26

DIRECTOR DEALINGS: 4d Pharma Chair Buys GBP15,000 In Shares

LONDON (Alliance News) - 4d Pharma PLC on Thursday said that Chair David Norwood acquired 15,000 shares in the company.On Wednesday, Norwood bought the shares at 100.00 pence each for a of

Read more
21 May 2019 11:27

4D Pharma losses widen as it spends cash on development activities

(Sharecast News) - Biotherapeutics development company 4D Pharma reported net assets of £45.8m in its final results on Tuesday, falling from £69.8m year-on-year.

Read more
21 May 2019 10:29

4d Pharma Annual Loss Widens On Live Biotherapeutic Development Costs

LONDON (Alliance News) - 4d Pharma PLC on Tuesday said its loss widened in 2018 on research and development costs as it continued to develop its live biotherapeutic products, which contain living

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.